LINKS
- Access to medicines
  
  Click here for more information about our commitment.
  
  Joint efforts
  
  Transparency
  
  Information for Download
  
  Taking on responsibility
  (PDF, 1 MB)
Printer friendly version
Bookmark this page
gross

Patient-aid programs

Many people do not have access to appropriate healthcare – and not only in developing countries, but also in emerging economies such as China, Brazil, Egypt, Russia or Romania. Aid programs are necessary. Not only the typical diseases of poverty require treatment, but often the same illnesses as in industrialized countries: cancer, diabetes and cardiovascular diseases. In such cases, Bayer Schering Pharma is helping to close gaps in the provision of medical care by public health systems.

In industrialized countries, too, there are many people who cannot afford life-saving but cost-intensive therapies. We offer aid programs in order to reach these people and enable them to receive effective treatment.

In Asia for example, Bayer Schering Pharma launched the first access program in 2007 for patients who receive the drug containing the active substance sorafenib for renal-cell carcinoma. Once the diagnosis has been confirmed, selected centers assess whether the patient can be accepted into the program. Other programs are planned.

In the USA, the company launched a support program for people suffering from MS. In order to be eligible, patients must meet certain criteria as regards their insurance cover and financial situation. Furthermore, the program provides doctors and patients with a complete support network, supplying them with the latest information about MS.